Placebo to boceprevir

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HCV InfectionHIV InfectionsHepatitis CHepatitis C, Chronic

Phase 2

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

CompletedNCT00959699

Merck Sharp & Dohme LLCHCV Infection, Hepatitis C, HIV Infections

Start: 2009-11-30End: 2012-10-31Updated: 2017-04-07

Phase 3

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

CompletedNCT01390844

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2011-10-21End: 2015-06-19Updated: 2018-09-11

Related Papers

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

2013-06-12140 citations